Learn more about our mission

Next generation technologies

The Institute for Biomarker Research (IBR), a member of Genesis Biotechnology Group, was established in 2014 with the mission of developing molecular-based diagnostics and pharmacogenomic biomarkers in oncology, infectious disease and obstetrics and gynecology.

IBR is dedicated to the innovation of multi-variant-based personal diagnostics to assess disease evaluation, progression, regression, and patient stratification to establish a targeted, pharmacogenomic-based treatment approach tailored to every patient’s specific clinical situation.

Utilizing cutting-edge technologies, such as next generation DNA sequencing, IBR is focused on the creation, validation and commercialization of innovative diagnostic assays for clinical practice. IBR offers diverse panels and packages of biomarkers for a variety of medical conditions. Our innovative genetic testing menu assists in risk assessment, prevention, diagnosis and treatment of cancer and infections. Performing enhanced screening for genes mutation carriers and family members significantly improves medical outcomes, and reduces medical costs through early diagnosis and early treatment.

IBR’s team includes experienced scientific researchers, research physicians, and technicians who provide state-of-the-art services for our customers. Well-founded collaborations with national research leaders help us to provide the highest quality up-to-date services possible today and in the future.

We are 100% customer oriented and provide immediate response to requests and suggestions from our clients, physicians and patients, in order to improve our service and make them feel confident and informed.

Meet our team
Previous Screen

Dr. Martin Adelson is a graduate of the Fels Institute for Cancer Research and Molecular Biology at Temple University and a recipient of the prestigious Daniel Swern Memorial Fellowship. While in graduate school, Dr. Adelson’s research was focused on the modulation of a natural antiviral enzyme, PKR, to provide cells with the ability to resist infection with the human immunodeficiency virus (HIV-1). Later, he went on to complete his postdoctoral studies at the University of Medicine and Dentistry of New Jersey in the field of HIV-1-based gene therapy and became the recipient of a competitive Postdoctoral Research Fellowship from the National Institutes of Health, National Lung, and Blood Institute entitled, “Pseudotyped Lentiviral Vector Gene Therapy of Hemophilia”.

In 2002, Dr. Adelson began his appointment at Medical Diagnostic Laboratories, LLC (MDL) as the Director of Research and Development and quickly became known for his expertise in the development of diagnostic assays. In the following years, Dr. Adelson led the investigation of co-infection agents aspects of Lyme disease, partnered with physicians and researchers throughout the United States on studies around clinical pathogen prevalence, and oversaw development of new clinical diagnostic assays. Dr. Adelson is also known for his innovative work in areas of laboratory automation. In 2010, as the Principal Investigator, he became a recipient of a Small Business Innovative Research (SBIR) funding grant for the development of the acoustic dispensation of nanodrops of reagents to achieve a very high-throughput of PCR-based diagnostics. Dr. Adelson has implemented various innovations and re-engineering initiatives, as well as leveraged customized technology solutions, to re-calibrate and enhance MDL’s work flow. In multiple iterations, he directly formulated the work flow and authored all of the underlying software. Each modification has resulted in a qualitatively new level of testing quality and diagnostic test throughput while reducing overall business costs.

Dr. Adelson is the author of more than 45 publications and 65 abstracts, a member of the American Society of Microbiology, the International Organization for Mycoplasmology, and the Association for Molecular Pathology. He served as a reviewer on the peer-reviewed Journal of Clinical Microbiology and Diagnostic Microbiology and The Journal of Infectious Diseases. He is also a member of the Thomas Jefferson University Biotechnology Advisory Committee, an Associate Professor at Rowan University, a Medical Director for the Wadsworth Center New York State Department of Health, on the Scientific Advisory Board of JBS Science Inc. at the PA Biotechnology Center, and a founding member of the New Jersey and Pennsylvania BioTech and Life Sciences Leadership Council. Now as the Chief Operating Officer of the Genesis Biotechnology Group, Dr. Adelson leads clinical, development, and discovery research operations in MDL, Venenum Biodesign, LLC, and Invivotek, LLC, with his main focus being shifted to scaling and expanding the existing business infrastructure through both organic growth and corporate acquisition.

Martin E. Adelson, Ph.D.

Chief Operating Officer

Martin E. Adelson

Paul Aiyetan obtained his MD degree in 2005. He obtained an MS in 2011 and completed a Postdoctoral Pathology Fellowship in 2015. He joined the Genesis Biotechnology Group in 2016. His current focus is on the utility of multidimensional data to facilitate an understanding of the etiology, pathogenesis, diagnosis, prognosis, treatment and prevention of complex diseases – a fundamental tenet of precision medicine. He has 14 peer-reviewed publications.

Paul Aiyetan, M.D., M.S.

Bioinformatics Scientist

Paul Aiyetan

Thais Acquafreda graduated from the School of Dentistry, University of Sao Paulo, Brazil, in 2003. She obtained an M.S. in 2006 and a Ph.D. in 2009, both in Oral Pathology. She joined the Genesis Biotechnology Group in 2015 and serves as a Research Scientist in The Institute for Biomarker Research. Thais is currently involved in cell-based assay development for prognosis in malignant disease. Her focus is on functional evaluation of somatic mutations in personalized medicine. She has 3 peer-reviewed publications.

Thais Acquafreda Antunes, D.D.S., M.D.S., Ph.D.

Research Scientist

Thais Acquafreda Antunes

Charronne Davis obtained her B.S. in 2004 and joined the Genesis Biotechnology Group in 2007. She currently serves as a Research Associate in The Institute for Biomarker Research. Charronne has developed and released multiple molecular diagnostic tests for GBG and released them into the CLIA certified clinical laboratory. Her current focus is on gene-expression assays to detect gynecological viral pathogens. She has 5 peer-reviewed publications and is an inventor on 3 published or issued US patents.

Charronne Davis, B.S.

Research Associate

Charronne Davis

Michael DiCola obtained his B.S. in Biotechnology in 1996 and joined the Genesis Biotechnology Group in 2015. He currently serves as a Research Associate in the Institute for Biomarker Research with responsibility for the development of genetic predisposition assays using next-generation sequencing (NGS). His current focus is on the development, validation, and clinical release of an extended gene panel test for hereditary breast cancer. He has 7 peer-reviewed publications and is an inventor on 1 issued US patent.

Michael Dicola, B.S.

Research Associate

Michael Dicola

Thuy Do obtained her Ph.D. in 2007 and joined the Genesis Biotechnology Group in 2008. She currently serves as a Research Scientist in The Institute for Biomarker Research. She has developed many nucleic acid-based diagnostic tests for GBG and released them into the CLIA certified clinical laboratory. Her current focus is on the development and validation of qRT-PCR and next-generation sequencing tools for heritable malignant and non-malignant disorders. She has 5 peer-reviewed publications and is an inventor on 2 published or issued US patents.

Thuy Do, Ph.D.

Research Scientist

Thuy Do

Grant Gallagher obtained his Ph.D. in 1984 and joined the Genesis Biotechnology Group in 2006. He currently serves as a Senior Team Leader in The Institute of Biomarker Research. Grant has a special interest in Immunology and Genetics in autoimmunity, and the development of novel molecular prognostic tools in malignant disease and other hereditary conditions. He also co-directs drug discovery programs in immuno-oncology. He has 86 peer-reviewed publications and is an inventor on 25 published or issued US patents.

Grant Gallagher, Ph.D.

Senior Team Leader

Tatyana Naryshkina obtained her Ph.D. in 2000 and joined the Genesis Biotechnology Group in 2015. She currently serves as a Research Scientist in the Institute for Biomarker Research. Tatyana is currently involved in cell-based assay development for prognosis in malignant disease. Her current focus is on functional evaluation of somatic mutations in personalized medicine. She has 14 peer-reviewed publications.

Tatyana Naryshkina, Ph.D.

Research Scientist

Tatyana Naryshkina

Utsav Patel obtained his B.A. in 2013 and joined the Genesis Biotechnology Group in 2014. He currently serves as a Research Associate in The Institute for Biomarker Research. He has assisted in developing and validating next-generation sequencing assays to detect viral infection. His current focus is on developing and validating next-generation diagnostic tests for cardiogenomics and breast cancer gene expression profiling.

Utsav Patel, B.A.

Research Associate

Utsav Patel

Ani Qu obtained her Ph.D. in 2007 and joined the Genesis Biotechnology Group in 2013. She currently serves as a Research scientist in The Institute for Biomarker Research, with responsibility for the development of novel molecular diagnostic tools. In 2014, she released the molecular genetic test for germline mutations associated with Hereditary Breast and Ovarian Cancer into the CLIA certified clinical laboratory. Her current focus is on noninvasive prenatal testing. She has 15 peer-reviewed publications.

Ani Qu, Ph.D.

Research Scientist

Ani Qu

Rob Swanson obtained his Ph.D. in 1988 and joined the Genesis Biotechnology Group in 2010. He currently serves as a Team Leader in the Institute for Biomarker Research. Rob has responsibility for the development of advanced diagnostics. His current work is focused on infectious disease and on biomarkers associated with cancer progression. He has 21 peer-reviewed publications and two patents.

Robert Swanson, Ph.D.

Team Leader

Jason Trama obtained his Ph.D. in 2002 from the University of California, San Diego and joined the Genesis Biotechnology Group in 2003. He currently serves as Team Leader of Clinical Affairs in The Institute of Biomarker Research. Jason has an interest in cancer biology and the development and marketing of tests for malignant disease and hereditary conditions. He also contributes to drug discovery programs in oncology. He has 25 peer-reviewed publications and is an inventor on 8 issued patents.

Jason Trama, Ph.D.

Team Leader

Jason Trama

Elisa Waxman obtained her Ph.D. in 2006 and joined the Genesis Biotechnology Group in 2011. She currently serves as Team Leader in the Institute for Biomarker Research. Elisa is currently involved in cell-based assay development for prognosis in malignant disease. Her current focus is on functional evaluation of somatic mutations in personalized medicine. She has 12 peer-reviewed publications.

Elisa A. Waxman, Ph.D.

Team Leader

Elisa A. Waxman

Sanese White-Brown obtained her M.S. in 2012 and joined the Genesis Biotechnology Group in 2014. She currently serves as a Research Associate in the Institute for Biomarker Research, with responsibility for the creation and validation of genetic predisposition assays using next-generation sequencing (NGS). Her current focus is on the development and validation of an extended gene panel test for hereditary breast cancer. She has 2 peer-reviewed publications.

Sanese White-Brown, M.S.

Research Associate

Sanese White-Brown

Raymond Yu obtained his Ph.D. in 2002 and joined the Genesis Biotechnology Group in 2008. He currently serves as a Team Leader in the Institute for Biomarker Research. Raymond is currently involved in cell-based assay development for prognosis in malignant disease. His current focus is on functional evaluation of somatic mutations in personalized medicine. He has 15 peer-reviewed publications and is an inventor on 11 published or issued US patents.

Yick-Loi Raymond Yu, Ph.D.

Team Leader

Yick-Loi Raymond Yu
Cancel

Thank you!

Your message has been sent successfully.